

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s creatine/cn
L1 1 CREATINE/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 57-00-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatine (8CI)
OTHER NAMES:
CN Cosmocair C 100
CN Methylguanidoacetic acid
CN N-Methyl-N-guanylglycine
CN NSC 8752
CN Phosphagen
FS 3D CONCORD
MF C4 H9 N3 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PROMT, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


6238 REFERENCES IN FILE CA (1907 TO DATE)
129 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6248 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s creatine phosphate/cn
L2 1 CREATINE PHOSPHATE/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 67-07-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Sarcosine, N-(phosphonoamidino)- (8CI)
OTHER NAMES:
CN Creatine phosphate
CN Creatinephosphoric acid
CN N-(Phosphonoamidino)sarcosine
CN N-Phosphorocreatine
CN N-Phosphorylcreatine

CN Phosphocreatine
 CN Phosphorylcreatine
 FS 3D CONCORD
 MF C4 H10 N3 O5 P
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
 CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, PROMT, PROUSDDR, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7250 REFERENCES IN FILE CA (1907 TO DATE)
 24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 7256 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

| => file caplus | | SINCE FILE | TOTAL |
|----------------------|--|------------|---------|
| COST IN U.S. DOLLARS | | ENTRY | SESSION |
| FULL ESTIMATED COST | | 14.20 | 14.68 |

FILE 'CAPLUS' ENTERED AT 10:41:58 ON 19 MAY 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 May 2006 VOL 144 ISS 22
 FILE LAST UPDATED: 18 May 2006 (20060518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1
 L3 6248 L1

=> s l1 full
 L4 6248 L1

=> s l2 full
 L5 7256 L2

=> s (14 or 15) and (glutamate excitotoxicity or benoquinone or nicotinamide or spin traps or growth factor or aspirin or nitric oxide synthase or cyclooxygenase 2 or ICE or neuroimmunophilis or acetylcysteine or antioxidants or lipoic acid or cofactors or riboflavin or CoQ10)

101271 GLUTAMATE
1106 GLUTAMATES
101673 GLUTAMATE
 (GLUTAMATE OR GLUTAMATES)
10 EXCITOTOXITY
2 GLUTAMATE EXCITOTOXITY
 (GLUTAMATE (W) EXCITOTOXITY)
3 BENOQUINONE
21498 NICOTINAMIDE
405 NICOTINAMIDES
21607 NICOTINAMIDE
 (NICOTINAMIDE OR NICOTINAMIDES)
388858 SPIN
27833 SPINS
397482 SPIN
 (SPIN OR SPINS)
52780 TRAPS
794 SPIN TRAPS
 (SPIN (W) TRAPS)
1264765 GROWTH
4332 GROWTHS
1266975 GROWTH
 (GROWTH OR GROWTHS)
964211 FACTOR
864846 FACTORS
1520814 FACTOR
 (FACTOR OR FACTORS)
181289 GROWTH FACTOR
 (GROWTH (W) FACTOR)
19 ASPRIN
168834 NITRIC
3 NITRICS
168837 NITRIC
 (NITRIC OR NITRICS)
1650577 OXIDE
340086 OXIDES
1747239 OXIDE
 (OXIDE OR OXIDES)
95524 SYNTHASE
5552 SYNTHASES
96511 SYNTHASE
 (SYNTHASE OR SYNTHASES)
31243 NITRIC OXIDE SYNTHASE
 (NITRIC (W) OXIDE (W) SYNTHASE)
24882 CYCLOOXYGENASE
835 CYCLOOXYGENASES
25088 CYCLOOXYGENASE
 (CYCLOOXYGENASE OR CYCLOOXYGENASES)
8739174 2
9878 CYCLOOXYGENASE 2
 (CYCLOOXYGENASE (W) 2)
109684 ICE
1815 ICES
110182 ICE
 (ICE OR ICES)
0 NEUROIMMUNOPHILIS
6331 ACETYL CYSTEINE
10 ACETYL CYSTEINES
6333 ACETYL CYSTEINE
 (ACETYL CYSTEINE OR ACETYL CYSTEINES)
95966 ANTIOXIDANTS
3708 LIPOIC
4148725 ACID
1523480 ACIDS
4638801 ACID
 (ACID OR ACIDS)
3665 LIPOIC ACID
 (LIPOIC (W) ACID)

10539 COFACTORS
13435 RIBOFLAVIN
63 RIBOFLAVINS
13445 RIBOFLAVIN
(RIBOFLAVIN OR RIBOFLAVINS)

L6 831 COQ10
454 (L4 OR L5) AND (GLUTAMATE EXCITOTOXITY OR BENOQUINONE OR NICOTIN AMIDE OR SPIN TRAPS OR GROWTH FACTOR OR ASPIRIN OR NITRIC OXIDE SYNTHASE OR CYCLOOXYGENASE 2 OR ICE OR NEUROIMMUNOPHILIS OR ACETYLCYSTEINE OR ANTIOXIDANTS OR LIPOIC ACID OR COFACTORS OR RIBOFLAVIN OR COQ10)

=> s 16 and parkinson?

23582 PARKINSON?

L7 14 L6 AND PARKINSON?

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:216951 CAPLUS

DOCUMENT NUMBER: 144:267302

TITLE: Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.

INVENTOR(S): Antosh, Stanley Charles; Meduri, Anthony J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| US 2006052448 | A1 | 20060309 | US 2004-711255 | 20040904 |
| WO 2006028948 | A2 | 20060316 | WO 2005-US31249 | 20050831 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |


PRIORITY APPLN. INFO.: US 2004-711255 A 20040904

AB The present invention relates to the use of Me pyruvic acid (a Me ester of pyruvic acid) and/or Me pyruvate (Me pyruvate is the ionized form of Me pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular energy production. Me pyruvate compds. can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination disorders, or cellular disorders which interfere with the energy metabolism of neurons and mitochondrial diseases. Use of Me pyruvate and/or Me pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. Treatment can be effective even when administered after the onset of an ischemic event that triggers neurodegeneration. In the following text, the terms "methyl pyruvate, Me


pyruvate compds., Me pyruvic acid" are used interchangeably.
 IT 57-00-1, Creatine 57-00-1D, Creatine, analogs
 . 67-07-2, Creatine phosphate 67-07-2D,
 N-Phosphocreatine, analogs
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of Me pyruvate or Me pyruvic acid for treatment of diseases of
 nervous system and neuronal degeneration caused by defective
 intracellular energy production and combination with other agents)
 RN 57-00-1 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 57-00-1 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
 CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
 CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:147331 CAPLUS
 DOCUMENT NUMBER: 144:219283
 TITLE: Physiologically acceptable composition containing
 alpha-lipoic acid, creatine, and a
 phosphatide
 INVENTOR(S): Schuhbauer, Hans; Jaeger, Ralf; Purpura, Martin
 PATENT ASSIGNEE(S): Bioghurt Biogarde GmbH & Co. KG, Germany
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2006015774 | A1 | 20060216 | WO 2005-EP8375 | 20050802 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, | | | |

NG, NI, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

DE 102004038155 A1 20060316 DE 2004-102004038155 20040806

DE 2004-102004038155A 20040806

PRIORITY APPLN. INFO.: AB Disclosed is a novel physiol. acceptable composition substantially containing α - lipoic acid, creatine and a phosphatide and/or one of the suitable derivs. thereof. Said composition preferably contains 0.01 to 80 % by weight of the lipoic acid component, 1.0 to 99.9 % of the creatine component, and 0.01 to 80 % by weight of the phosphatide component and is used mainly for slowing down degenerative and particularly progressive modifications of the brain. Forms of administration such as food supplements, food, beverages, medicaments, cosmetics are particularly suitable. In general, the disclosed composition is used in individual doses ranging between 10 mg and 10 g. The inventive combination makes it possible to obtain results which additively exceed the effects of the individual compds. while representing cases of application that were unknown for the individual compds. Thus a gelatin capsule contained (mg): (\pm)- α - lipoic acid 60; creatine monohydrate 400; phosphatidylserine 40.


IT 57-00-1, Creatine 67-07-2, Creatine phosphate

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(physiol. acceptable composition containing alpha-lipoic acid, creatine, and a phosphatide)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1310905 CAPLUS

DOCUMENT NUMBER: 144:45513

TITLE: Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same, and uses thereof

INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S. Ser. No. 906,303.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

| | | | | |
|---|----|-----------------|-----------------|----------|
| US 2005276872 | A1 | 20051215 | US 2005-117760 | 20050427 |
| US 2003091669 | A1 | 20030515 | US 2001-944805 | 20010831 |
| US 6616943 | B2 | 20030909 | | |
| WO 2003017919 | A2 | 20030306 | WO 2002-IB4750 | 20020828 |
| WO 2003017919 | A3 | 20040722 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004146591 | A1 | 20040729 | US 2003-471384 | 20030904 |
| WO 2005037200 | A2 | 20050428 | WO 2004-US33359 | 20041008 |
| WO 2005037200 | A3 | 20050616 | | |
| WO 2005037200 | C1 | 20050901 | | |
| WO 2005037200 | B1 | 20051006 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2005063273 | A1 | 20050714 | WO 2004-US43465 | 20041223 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005220910 | A1 | 20051006 | US 2005-906303 | 20050214 |
| WO 2006029221 | A2 | 20060316 | WO 2005-US31900 | 20050907 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 2001-944805 | A2 | 20010831 |
| | | WO 2002-IB4750 | W | 20020828 |
| | | US 2003-471384 | A2 | 20030904 |
| | | US 2003-509851P | P | 20031009 |
| | | US 2003-532101P | P | 20031223 |
| | | US 2004-607858P | P | 20040907 |
| | | US 2004-613811P | P | 20040927 |
| | | US 2004-617379P | P | 20041008 |
| | | WO 2004-US33359 | A2 | 20041008 |
| | | WO 2004-US43465 | A2 | 20041223 |

| | |
|-----------------|-------------|
| US 2005-906303 | A2 20050214 |
| US 2005-117760 | A 20050427 |
| US 2005-675282P | P 20050427 |
| US 2005-675284P | P 20050427 |
| US 2005-131551 | A 20050517 |

OTHER SOURCE(S): MARPAT 144:45513

AB This invention provides compns., methods and process of producing exts. and pure compds. from *Xanthoceras sorbifolia*. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compds. of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or/and 22, or/and linked to the sugar. The compds. of the present invention have various pharmaceutical and therapeutic applications.


IT 57-00-1, Creatine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(*Xanthoceras sorbifolia* extract composition, isolated compds., preparation methods, and therapeutic use)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:369224 CAPLUS

DOCUMENT NUMBER: 142:423889

TITLE: Composition comprising *Xanthoceras sorbifolia* extracts, isolated compounds, preparation methods, and therapeutic use

INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun

PATENT ASSIGNEE(S): Pacific Arrow Limited, Peop. Rep. China

SOURCE: PCT Int. Appl., 237 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2005037200 | A2 | 20050428 | WO 2004-US33359 | 20041008 |
| WO 2005037200 | A3 | 20050616 | | |
| WO 2005037200 | C1 | 20050901 | | |
| WO 2005037200 | B1 | 20051006 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, | | | |

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

| | | | | |
|---------------|--|----------|-----------------|----------|
| WO 2005063273 | A1 | 20050714 | WO 2004-US43465 | 20041223 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2005220910 | A1 | 20051006 | US 2005-906303 | 20050214 |
| US 2005245470 | A1 | 20051103 | US 2005-117745 | 20050427 |
| US 2005276872 | A1 | 20051215 | US 2005-117760 | 20050427 |
| US 2005277601 | A1 | 20051215 | US 2005-131551 | 20050517 |
| WO 2006029221 | A2 | 20060316 | WO 2005-US31900 | 20050907 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.:

| | |
|-----------------|-------------|
| US 2003-509851P | P 20031009 |
| US 2003-532101P | P 20031223 |
| US 2001-944805 | A2 20010831 |
| WO 2002-IB4750 | W 20020828 |
| US 2003-471384 | A2 20030904 |
| US 2004-607858P | P 20040907 |
| US 2004-613811P | P 20040927 |
| US 2004-617379P | P 20041008 |
| WO 2004-US33359 | A 20041008 |
| WO 2004-US43465 | A2 20041223 |
| US 2005-906303 | A2 20050214 |
| US 2005-117745 | A2 20050427 |
| US 2005-117760 | A 20050427 |
| US 2005-675282P | P 20050427 |
| US 2005-675284P | P 20050427 |
| US 2005-131551 | A 20050517 |

OTHER SOURCE(S):

MARPAT 142:423889


AB The invention provides compns., methods and process of producing exts. from *Xanthoceras sorbifolia*. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for anticancer, preventing cerebral aging, improving memory, improving cerebral functions and curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease and other diseases caused by cerebral dysfunction, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder and treating impotence and premature ejaculation. The invention provides compds. comprise a sugar, terepene, e.g. sapogenin, and a side chains at carbon 21 and 22, e.g. angeloyl groups. The compds. of the invention have various pharmaceutical and therapeutic applications.

IT 57-00-1, Creatine


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(*Xanthoceras sorbifolia* extract composition, isolated compds., preparation methods,

and therapeutic use)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:983902 CAPLUS
DOCUMENT NUMBER: 142:425007
TITLE: *Caenorhabditis elegans* MPP Model of **Parkinson**'s Disease for High-Throughput Drug Screenings
AUTHOR(S): Braungart, Evelyn; Gerlach, Manfred; Riederer, Peter; Baumeister, Ralf; Hoener, Marius C.
CORPORATE SOURCE: Pieris Proteolab AG, Freising-Weihenstephan, Germany
SOURCE: *Neurodegenerative Diseases* (2004), 1(4-5), 175-183
CODEN: NDEIA6; ISSN: 1660-2854
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The neurotoxin MPTP and its active metabolite MPP+ cause **Parkinson**'s disease (PD)-like symptoms in vertebrates by selectively destroying dopaminergic neurons in the substantia nigra. MPTP/MPP+ models have been established in rodents to screen for pharmacol. active compds. In addition to being costly and time consuming, these animal models are not suitable for large scale testings using compound libraries. The authors present a novel MPP+-based model for high-throughput screenings using the nematode *Caenorhabditis elegans*. Incubation of *C. elegans* with MPTP or its active metabolite MPP+ resulted in strong symptomatic defects including reduced mobility and increased lethality, and is correlated with a specific degeneration of the dopaminergic neurons. The phenotypic consequences of MPTP/MPP+ treatments were recorded using automated hardware and software for quantification. Incubation of *C. elegans* with a variety of pharmacol. active components used in PD treatment reduced the MPP+-induced defects. These data suggest that the *C. elegans* MPTP/MPP+ model can be used for the quant. evaluation of anti-PD drugs.
IT 57-00-1, Creatine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (*Caenorhabditis elegans* MPP model of **Parkinson**'s disease for high-throughput drug screenings)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:934313 CAPLUS
DOCUMENT NUMBER: 141:400910
TITLE: Medical composition for balancing bodily processes
INVENTOR(S): Bland, Jeffrey S.; Liska, Deann J.; Krumhar, Kim Carleton; Tripp, Matthew L.; Darland, Gary K.; Lerman, Robert H.; Lukaczer, Daniel O.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 352,388.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 2004220118 | A1 | 20041104 | US 2003-735526 | 20031211 |
| US 2002192310 | A1 | 20021219 | US 2002-56858 | 20020123 |
| US 2003190381 | A1 | 20031009 | US 2003-352388 | 20030127 |
| PRIORITY APPLN. INFO.: | | | US 2001-265908P | P 20010202 |
| | | | US 2002-56858 | A2 20020123 |
| | | | US 2002-352016P | P 20020125 |
| | | | US 2002-432689P | P 20021211 |
| | | | US 2003-352388 | A2 20030127 |


AB Medical compns. and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed. A medical composition in the form of tablets for nutritional support of women with symptoms associated with hormone cycles contained vitamin A 2500 IU, vitamin D 200 IU, vitamin E 200 IU, vitamin K 40 mcg, vitamin B6 50 mg, vitamin B12 30 mcg, folic acid 800 mcg, isoflavones 100 mg, curcumin 200 mg, trimethylglycine 200 mg, resveretrol 2 mg, rosemary extract 200 mg, and chrysin 100 mg. The effects of the tablets was clin. studied in women.

IT 57-00-1, Creatine

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(medical composition for balancing bodily processes)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:949255 CAPLUS

DOCUMENT NUMBER: 140:210533

TITLE: Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

AUTHOR(S): Klivenyi, Peter; Gardian, Gabrielle; Calingasan, Noel Y.; Yang, Lichuan; Beal, M. Flint

CORPORATE SOURCE: Department of Neurology and Neuroscience, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, 10021, USA

SOURCE: Journal of Molecular Neuroscience (2003), 21(3), 191-198

CODEN: JMNEES; ISSN: 0895-8696

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB There is evidence that both inflammatory mechanisms and mitochondrial dysfunction contribute to Parkinson's disease (PD) pathogenesis. We investigated whether the cyclooxygenase 2 (COX-2) inhibitor rofecoxib either alone or in combination with creatine could exert neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of PD in mice. Both rofecoxib and creatine administered alone protected against striatal dopamine depletions and loss of substantia nigra tyrosine hydroxylase immunoreactive neurons. Administration of rofecoxib with creatine produced significant additive neuroprotective effects against dopamine depletions. These results suggest that a combination of a COX-2 inhibitor with creatine might be a useful neuroprotective strategy for PD.

IT 57-00-1, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(additive neuroprotective effects of creatine and a
cyclooxygenase 2 inhibitor against dopamine depletion
in mouse model of Parkinson's disease)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:855794 CAPLUS

DOCUMENT NUMBER: 139:345938

TITLE: Combination therapy including cyclooxygenase 2 (COX2) inhibitor(s) for the treatment of Parkinson's disease

INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003088958 | A2 | 20031030 | WO 2003-US11269 | 20030414 |
| WO 2003088958 | A3 | 20040819 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2481934 | AA | 20031030 | CA 2003-2481934 | 20030414 |
| AU 2003223579 | A1 | 20031103 | AU 2003-223579 | 20030414 |
| US 2004034083 | A1 | 20040219 | US 2003-413348 | 20030414 |
| EP 1494664 | A2 | 20050112 | EP 2003-719717 | 20030414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003009259 | A | 20050209 | BR 2003-9259 | 20030414 |
| JP 2005528403 | T2 | 20050922 | JP 2003-585710 | 20030414 |
| PRIORITY APPLN. INFO.: | | | US 2002-373311P | P 20020418 |
| | | | WO 2003-US11269 | W 20030414 |


OTHER SOURCE(S): MARPAT 139:345938

AB The invention discloses a method for treating, preventing, or inhibiting Parkinson's disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective

amount
 IT 57-00-1, Creatine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (combination therapy including **cyclooxygenase 2**
 inhibitor for treatment of **Parkinson's disease**)
 RN 57-00-1 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:765720 CAPLUS
 DOCUMENT NUMBER: 140:174175
 TITLE: Targeting cellular energy production in neurological disorders
 AUTHOR(S): Baker, Steven K.; Tarnopolsky, Mark A.
 CORPORATE SOURCE: Department of Medicine, Neurology and Rehabilitation,
 McMaster University, Hamilton, ON, L8N 3Z5, Can.
 SOURCE: Expert Opinion on Investigational Drugs (2003),
 12(10), 1655-1679
 CODEN: EOIDER; ISSN: 1354-3784
 PUBLISHER: Ashley Publications Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. The concepts of energy dysregulation and oxidative stress and their complicated interdependence have rapidly evolved to assume primary importance in understanding the pathophysiol. of numerous neurol. disorders. Therefore, neuroprotective strategies addressing specific bioenergetic defects hold particular promise in the treatment of these conditions (i.e., amyotrophic lateral sclerosis, Huntington's disease, **Parkinson's disease**, Friedreich's ataxia, mitochondrial cytopathies and other neuromuscular diseases), all of which, to some extent, share the final common pathway leading to cell death through either necrosis or apoptosis. Compds. such as creatine monohydrate and coenzyme Q10 offer substantial neuroprotection against ischemia, trauma, oxidative damage and neurotoxins. Miscellaneous agents, including α -lipoic acid, β -OH- β -methylbutyrate, riboflavin and nicotinamide, have also been shown to improve various metabolic parameters in brain and/or muscle. This review will highlight the biol. function of each of the above mentioned compds. followed by a discussion of their utility in animal models and human neurol. disease. The balance of this work will be comprised of discussions on the therapeutic applications of creatine and coenzyme Q10.
 IT 57-00-1, Creatine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (targeting cellular energy production in neurol. disorders)
 RN 57-00-1 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 330 THERE ARE 330 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:319452 CAPLUS

DOCUMENT NUMBER: 138:314630
 TITLE: Orthomolecular sulfo-adenosylmethionine derivatives
 INVENTOR(S): Wilburn, Michael D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|-------------------|----------|-----------------|----------|
| US 2003078231 | A1 | 20030424 | US 2001-886612 | 20010622 |
| PRIORITY APPLN. INFO.: | | | US 2001-886612 | 20010622 |
| OTHER SOURCE(S): | MARPAT 138:314630 | | | |
| GI | | | | |




AB Disclosed are orthomol. sulfo-adenosylmethionine derivative compds., compns., and their uses for effecting a biol. activity in an animal, such as neurochem. activity; liver biol. activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compds. of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compds. of the present invention are I (R1 = H, C1-C10 alkyl, C2-C10 alkenyl or alkynyl, -C(O)R2; R2 = C1-C10 alkyl, C2-C10 alkenyl or alkynyl; Q = -C(NH3)C(O)AX, -C(COOH)NHX; A = O, N; X = a defined reaction product) or pharmaceutically acceptable salt, ester or solvate thereof. α -(S-adenosylmethionine)-O-tocopherol was prepared from N-Acetyl-S-benzyl-L-homocysteine, α -tocopherol, and 5'-O-p-Tolylsulfonyladenosine.

IT 57-00-1D, Creatine, reaction products with S-adenosyl-L-methionine derivs. 67-07-2D, Phosphocreatine, reaction products with S-adenosyl-L-methionine derivs.

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (orthomol. S-adenosyl-L-methionine derivs. with antioxidant properties)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:315166 CAPLUS
 DOCUMENT NUMBER: 139:316285
 TITLE: Bioenergetic approaches for neuroprotection in
 Parkinson's disease
 AUTHOR(S): Beal, M. Flint
 CORPORATE SOURCE: Department of Neurology and Neuroscience, New York
 Presbyterian Hospital, Weill Medical College of
 Cornell University, New York, NY, USA
 SOURCE: Annals of Neurology (2003), 53(Suppl. 3), S39-S48
 CODEN: ANNED3; ISSN: 0364-5134
 PUBLISHER: Wiley-Liss, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. There is considerable evidence suggesting that mitochondrial dysfunction and oxidative damage may play a role in the pathogenesis of *Parkinson's disease* (PD). This possibility has been strengthened by recent studies in animal models, which have shown that a selective inhibitor of complex I of the electron transport gene can produce an animal model that closely mimics both the biochem. and histopathol. findings of PD. Several agents are available that can modulate cellular energy metabolism and that may exert antioxidative effects. There is substantial evidence that mitochondria are a major source of free radicals within the cell. These appear to be produced at both the iron-sulfur clusters of complex I as well as the ubiquinone site. Agents that have shown to be beneficial in animal models of PD include creatine, coenzyme Q10, *Ginkgo biloba*, **nicotinamide**, and acetyl-L-carnitine. Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD. Similarly, coenzyme Q10 is also effective in animal models and has shown promising effects both in clin. trials of PD as well as in clin. trials in Huntington's disease and Friedreich's ataxia. Many other agents show good human tolerability. These agents therefore are promising candidates for further study as neuroprotective agents in PD.
 IT 57-00-1, Creatine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (bioenergetic approaches for neuroprotection in *Parkinson's disease*)
 RN 57-00-1 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:833099 CAPLUS
 DOCUMENT NUMBER: 135:362605
 TITLE: Nutritional preparation comprising ribose and folic
 acid and medical use thereof
 INVENTOR(S): Hageman, Robert Johan Joseph; Smeets, Rudolf Leonardus
 Lodewijk; Verlaan, George
 PATENT ASSIGNEE(S): N.V. Nutricia, Neth.
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001085178 | A1 | 20011115 | WO 2001-NL349 | 20010508 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6420342 | B1 | 20020716 | US 2000-566381 | 20000508 |
| EP 1282426 | A1 | 20030212 | EP 2001-930315 | 20010508 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003532679 | T2 | 20031105 | JP 2001-581831 | 20010508 |
| US 2002183263 | A1 | 20021205 | US 2002-178736 | 20020625 |
| US 6548483 | B2 | 20030415 | | |

PRIORITY APPLN. INFO.: US 2000-566381 A 20000508
 WO 2001-NL349 W 20010508


AB Trauma, surgery, inflammation, subfertility, lactation problems, gut disorders, infant nutrition, cancer, arthritis and other joint problems, vascular problems and cardio- or cerebrovascular problems, ischemia, aging, impaired immune function, burns, sepsis, malnutrition, problems with liver or kidneys, malaria, cystic fibrosis, migraine, neurol. problems, respiratory infections, improvement of sports results, muscle soreness, drug intoxication and pain can be treated with a nutritional composition containing effective amts. of ribose and folic acid, optionally combined with other components such as niacin, histidine, glutamine, orotate, vitamin B6 and other components.

IT 57-00-1, Creatine

RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional preparation comprising ribose and folic acid and medical use)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:659188 CAPLUS

DOCUMENT NUMBER: 131:281583

TITLE: Compositions containing a combination of a creatine compound and a neuroprotective compound for the treatment of nervous system diseases

INVENTOR(S): Kaddurah-Daouk, Rima; Beal, M. Flint

PATENT ASSIGNEE(S): Avicena Group, Inc., USA; The General Hospital Corporation

SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9951097 | A1 | 19991014 | WO 1999-US7340 | 19990402 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2327095 | AA | 19991014 | CA 1999-2327095 | 19990402 |
| AU 9933803 | A1 | 19991025 | AU 1999-33803 | 19990402 |
| AU 759467 | B2 | 20030417 | | |
| EP 1065931 | A1 | 20010110 | EP 1999-915245 | 19990402 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002510604 | T2 | 20020409 | JP 2000-541878 | 19990402 |
| PRIORITY APPLN. INFO.: | | | US 1998-80459P | P 19980402 |
| | | | US 1999-283267 | A 19990401 |
| | | | WO 1999-US7340 | W 19990402 |

OTHER SOURCE(S): MARPAT 131:281583

AB The invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate, or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compds. in combination with neuroprotective agents can be used as therapeutically effective compns. against a variety of diseases of the nervous system, e.g. diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compds. which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compds. which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of ATP and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphocreatine analogs bearing nontransferable moieties which mimic the N-phosphoryl group.

IT 57-00-1 57-00-1D, Creatine, analogs 67-07-2,


Creatine phosphate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(creatine compound-neuroprotective compound combination for treatment of nervous system disease)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:297312 CAPLUS
 DOCUMENT NUMBER: 130:320858
 TITLE: Nutritional supplement for cerebral metabolic insufficiencies
 INVENTOR(S): Blass, John P.
 PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 9921565 | A1 | 19990506 | WO 1998-US18120 | 19980901 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2306875 | AA | 19990506 | CA 1998-2306875 | 19980901 |
| AU 9892139 | A1 | 19990517 | AU 1998-92139 | 19980901 |
| AU 760140 | B2 | 20030508 | | |
| EP 1032403 | A1 | 20000906 | EP 1998-944644 | 19980901 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001521002 | T2 | 20011106 | JP 2000-517723 | 19980901 |
| US 6537969 | B1 | 20030325 | US 2000-529091 | 20001020 |
| US 2003176365 | A1 | 20030918 | US 2003-379816 | 20030304 |
| PRIORITY APPLN. INFO.: | | | US 1997-63165P | P 19971024 |
| | | | WO 1998-US18120 | W 19980901 |
| | | | US 2000-529091 | A1 20001020 |

AB The present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate, or salt thereof, or a precursor of a Krebs cycle intermediate. Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, α -ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixts. thereof. Precursors of Krebs cycle intermediates are compds. converted by the body to form a Krebs cycle intermediate. The present invention also relates to administration of the pharmaceutical composition to treat an individual for a disorder involving impaired mitochondrial function and to improve cerebral function in an individual having impaired cerebral metabolism


IT 57-00-1, Creatine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as adjuvant; nutritional supplements containing sugars and Krebs cycle intermediates for improving impaired mitochondrial functions)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:39:49 ON 19 MAY 2006)

FILE 'STNGUIDE' ENTERED AT 10:40:38 ON 19 MAY 2006

FILE 'HOME' ENTERED AT 10:40:45 ON 19 MAY 2006

FILE 'REGISTRY' ENTERED AT 10:40:53 ON 19 MAY 2006

L1 1 S CREATINE/CN

L2 1 S CREATINE PHOSPHATE/CN

FILE 'CAPLUS' ENTERED AT 10:41:58 ON 19 MAY 2006

L3 6248 S L1

L4 6248 S L1 FULL

L5 7256 S L2 FULL

L6 454 S (L4 OR L5) AND (GLUTAMATE EXCITOTOXITY OR BENOQUINONE OR NICO

L7 14 S L6 AND PARKINSON?

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 126.62 | 141.30 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | -10.50 | -10.50 |

STN INTERNATIONAL LOGOFF AT 10:52:46 ON 19 MAY 2006